WASHINGTON — The Food and Drug Administration on Monday expanded its approval­ of Johnson & Johnson’s prostate cancer pill, Zytiga, for men with an earlier stage of the disease.

The agency said Zytiga is now approved for late-stage prostate cancer patients who have not yet received chemotherapy, based on study results showing it can extend life by up to five months when taken by men in that group.